drugset
drugset / Trial / NCT05031624

A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects

NCT05031624 ↗

Phase 1 Completed 32 enrolled Celldex Therapeutics
RandomizedSequentialQuadruple-blindTreatment

Summary

This is a study to determine the safety and pharmacokinetics of CDX-0159 administered subcutaneously in healthy subjects.

Timeline

Start
2021-08-30
Primary completion
2022-01-14
Completion
2022-01-14

Drugs

EvaluationDrugModalityDoseRoute
Subject barzolvolimab Monoclonal antibody — Subcutaneous

Indications

No indication recorded.